BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The role of HDIs in combination with agents targeting the BCR/ABL oncoprotein has been investigated in chronic myeloid leukaemia (CML) for which the BCR/ABL tyrosine kinase inhibitor imatinib is now a standard therapy but resistance can develop.